Anthropic Secures $30 Billion Funding, European Biotech and Tech Firms Gain Major Investments

Anthropic, a leading AI company known for its chatbot Claude, has raised an impressive $30 billion in a recent funding round that values the firm at $350 billion. This influx of capital, backed by prominent investors including GIC, Nvidia, Coatue, and Founders Fund, is set to bolster Anthropic's competitiveness against major players like Google, Meta, and OpenAI. CFO Krishna Rao highlighted the growing significance of Claude in enterprise operations and noted that the funds will be directed towards enhancing product and model development for business applications.

On the European front, the newly formed European Life Sciences Coalition (ELSC) announced plans to manage over €24 billion in private capital to support biotech firms. Established by Forbion and other European investors, this coalition aims to attract private investments and prevent the migration of promising biotech companies to the US. Sander Slootweg, Managing Partner at Forbion, emphasized the coalition’s mission to restore institutional investor confidence in the European biotech sector.

In a related technology advancement, Munich-based drone manufacturer Quantum Systems secured a €150 million financing package from an alliance of financial institutions including the European Investment Bank, Deutsche Bank, Commerzbank, and KfW. This funding is intended to scale production capabilities and facilitate acquisitions, positioning Quantum Systems for significant growth.

Meanwhile, German industrial supplier Lapp reported a 6% revenue increase to €1.93 billion for fiscal year 2024/25, driven by strong double-digit growth in the US and Asia despite domestic market challenges. CEO Matthias Lapp expressed concerns about the sluggish reform pace in Germany, underscoring the need for government pragmatism and greater trust in entrepreneurs. Lapp called for less regulatory interference, arguing that business leaders understand best how to advance their companies amid transformative times.

These developments underscore robust investment momentum in AI and biotech sectors globally, alongside the ongoing challenges faced by German industrial firms in adapting to changing market and regulatory environments.